AEBP1 and metabolic dysfunction-associated steatohepatitis: In that study, however, AEBP1 expression relative to fibrosis was not investigated; thus, the current results extend these findings to indicate that AEBP1 expression in the liver parallels the onset of fibrosis in NASH and suggest that AEBP1 may represent a specific therapeutic target to prevent the development of NASH fibrosis.